Candel Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Needham, mass., april 25, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 american society of clinical oncology (asco) annual meeting taking place may 31 to june 4, 2024, in chicago, il. the first presentation will feature data from the ongoing phase 1 clinical trial of can-3110 in patients with recurrent high-grade glioma. the presentation will focus on patients recruited in cohort c, treated with multiple injections of can-3110 (up to six), demonstrating that this approach is both feasible and well tolerated...

Needham, mass., april 11, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation to can-2409, candel's most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.

Needham, mass., april 09, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the presentation of a poster during the american association for cancer research (aacr) annual meeting, taking place april 5 through 10 in san diego, which focused on a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures (tls), being developed as a novel therapeutic strategy for solid tumors from candel's enlighten™ discovery platform.

Needham, mass., april 04, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of can-2409 plus valacyclovir (prodrug), together with standard of care (soc) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (pdac). survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 society for immunotherapy (sitc) annual meeting. based on the data presented at sitc, the u...

Needham, mass., march 28, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (hsv-1) replication-competent viral immunotherapy candidate, can-3110, in patients with rhgg that has recurred after standard of care (soc) treatment. the data were presented today during the 5th glioblastoma drug development summit in boston, massachusetts.

Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024.

Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.

Shares of Candel Therapeutics Inc. CADL, +280.95% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment.

Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer. CAN-2409 data sends Candel Therapeutics stock up Patients on CAN-2409 showed a meaningful increase in survival in a Phase II study, as per the biotechnology company.

If investing were easy, everybody would do it, and we would all be rich. But that isn't the case.

Candel Therapeutics shares gained more than 37% after the biopharmaceutical firm announced that its pancreatic cancer therapeutic has received U.S. Food and Drug Administration (FDA) Fast Track Designation.

NEEDHAM, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that, in the second quarter of 2024, it expects to report topline overall survival data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment (ICI) in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC) who progressed while on treatment with PD-(L)1 inhibitor therapy (Cohort 2).

NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November:

NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences.